Dr Agarwals Health Care Ltd
Incorporated in 2010,[1]Dr. Agarwal’s Health Care offers a wide array of eye care services, which include cataract and refractive surgeries, consultations, diagnoses, and non-surgical treatments. Additionally, they provide optical products, contact lenses, accessories, and pharmaceutical items related to eye care. [2]
- Market Cap ₹ 14,164 Cr.
- Current Price ₹ 446
- High / Low ₹ 568 / 327
- Stock P/E 240
- Book Value ₹ 61.8
- Dividend Yield 0.00 %
- ROCE 5.94 %
- ROE 1.31 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 20.9% CAGR over last 5 years
Cons
- Stock is trading at 7.22 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 3.29% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of BSE 500 BSE Healthcare Nifty 500 BSE IPO BSE Allcap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 202 | 248 | 232 | 362 | 598 | 835 | 1,044 | 1,227 | |
| 186 | 202 | 199 | 275 | 436 | 611 | 795 | 937 | |
| Operating Profit | 16 | 46 | 33 | 86 | 162 | 224 | 249 | 289 |
| OPM % | 8% | 19% | 14% | 24% | 27% | 27% | 24% | 24% |
| 5 | 9 | 4 | 10 | -12 | 38 | 40 | 49 | |
| Interest | 20 | 42 | 34 | 38 | 64 | 88 | 94 | 75 |
| Depreciation | 21 | 49 | 55 | 59 | 92 | 129 | 156 | 183 |
| Profit before tax | -20 | -36 | -52 | -1 | -6 | 45 | 39 | 80 |
| Tax % | 0% | 0% | 4% | 55% | -641% | 47% | 43% | |
| -20 | -36 | -54 | -1 | 32 | 24 | 22 | 55 | |
| EPS in Rs | 0.69 | 1.75 | ||||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | 42% |
| TTM: | 24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 152% |
| TTM: | 201% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 7% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | 3% |
| Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 7 | 8 | 9 | 32 | 32 |
| Reserves | 290 | 248 | 194 | 192 | 554 | 1,218 | 1,902 | 1,924 |
| 135 | 142 | 161 | 252 | 590 | 661 | 568 | 589 | |
| 60 | 200 | 281 | 242 | 236 | 298 | 335 | 299 | |
| Total Liabilities | 492 | 596 | 643 | 692 | 1,388 | 2,187 | 2,837 | 2,844 |
| 99 | 322 | 387 | 367 | 907 | 1,302 | 1,591 | 1,769 | |
| CWIP | 1 | 3 | 11 | 2 | 35 | 9 | 18 | 5 |
| Investments | 238 | 146 | 121 | 147 | 187 | 629 | 729 | 670 |
| 154 | 124 | 124 | 176 | 258 | 248 | 498 | 400 | |
| Total Assets | 492 | 596 | 643 | 692 | 1,388 | 2,187 | 2,837 | 2,844 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 40 | 46 | 78 | 153 | 222 | 208 | ||
| -37 | -26 | -98 | -436 | -818 | -577 | ||
| -60 | -21 | 40 | 316 | 570 | 374 | ||
| Net Cash Flow | -56 | -1 | 20 | 33 | -26 | 5 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 46 | 46 | 39 | 31 | 24 | 22 | 25 |
| Inventory Days | 138 | 159 | 147 | 149 | 119 | 135 | 174 |
| Days Payable | 330 | 427 | 608 | 456 | 354 | 383 | 375 |
| Cash Conversion Cycle | -147 | -222 | -422 | -276 | -210 | -226 | -176 |
| Working Capital Days | 5 | -37 | -43 | -54 | -88 | -79 | -55 |
| ROCE % | 1% | -5% | 9% | 10% | 8% | 6% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Scheme of Arrangement
17 Feb - Exchange NOCs: NSE no-objection Feb16,2026; BSE no-adverse Feb17,2026 for AEHL-AHCL amalgamation.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
12 Feb - Of Schedule of Analyst / Investors Meet, is attached.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
10 Feb - Transcript of the Discussion held on the Unaudited Financial Results (Consolidated & Standalone) of the Company for the quarter and nine months ended December 2025, …
- Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011 7 Feb
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
4 Feb - Audio of Feb 4, 2026 analyst call on unaudited Q3/9M Dec 31, 2025 results available.
Concalls
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT
-
Sep 2025Transcript PPT
-
Aug 2025Transcript PPT REC
-
Jun 2025Transcript PPT
-
Feb 2025Transcript PPT REC
Largest Eyecare Service Provider[1]
Dr. Agarwal is India's largest eye care service chain with a 25% market share. It is the largest company by revenue in FY23, with more than two times the revenue from operations of the second-largest eye care service chain in the country.